ABUS vs DG · P/E 5.4, rev $6.2M vs P/E 15, rev $40.61B
Arbutus Biopharma Corp (ABUS) versus Dollar General Corporation (DG) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
Dollar General Corporation (DG) is a discount stores company listed on US.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported DG revenue for 2025-01-31 was $40.61B. Net income was $1.13B. Revenue was up 5.0% from 2024-02-02 to 2025-01-31. DG currently screens at market cap $22.87B and trailing P/E 14.7.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. DG currently screens at market cap $22.87B and trailing P/E 14.7.
Not investment advice. Open the ABUS and DG stock pages for the full models.
Not investment advice.